Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Department of Justice
Harvard Business School
Fuji
AstraZeneca
Moodys

Generated: May 22, 2019

DrugPatentWatch Database Preview

VIZAMYL Drug Profile

« Back to Dashboard

When do Vizamyl patents expire, and what generic alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-eight patent family members in twenty-four countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.

Summary for VIZAMYL
Drug patent expirations by year for VIZAMYL
Generic Entry Opportunity Date for VIZAMYL
Generic Entry Date for VIZAMYL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VIZAMYL
Synonyms for VIZAMYL
((18 sup)F)AH110690
[18F]-Flutemetamol
[18F]-Flutemetamol F18
[18F]AH110690
[18F]flutemetamol
18F-Flutemetamol
2-(3-((18 sup)F)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-(3-(sup 18)f)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-[3-((18)F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
2-[3-(18F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
6-Benzothiazolol, 2-(3-(fluoro-(sup 18)F)-4-(methylamino)phenyl)-
765922-62-1
CHEBI:76611
CHEMBL2042122
D10231
DB09151
DTXSID80227394
Flutemetamol
flutemetamol ((18)F)
Flutemetamol ((sup 18)F)
Flutemetamol ((sup18)F)
flutemetamol (18F)
Flutemetamol (18F) [INN]
Flutemetamol F 18
Flutemetamol F 18 (USAN)
Flutemetamol F 18 [USAN]
Flutemetamol F-18
Flutemetamol F18
GTPL7342
L49M066S0O
SCHEMBL10032147
UNII-L49M066S0O
Vizamyl (TN)

US Patents and Regulatory Information for VIZAMYL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for VIZAMYL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2182988 1590009-5 Sweden ➤ Sign Up PRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
1611115 92634 Luxembourg ➤ Sign Up PRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
2182988 CA 2015 00008 Denmark ➤ Sign Up PRODUCT NAME: RADIOAKTIVE ISOTOPER AF FLUTEMETAMOL, SAERLIGT FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140822
2182988 2015006 Norway ➤ Sign Up PRODUCT NAME: VIZAMYL; REG. NO/DATE: EU/1/14/941 20140822
2182988 122015000017 Germany ➤ Sign Up PRODUCT NAME: FLUTEMETAMOL (18F) IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/14/941 20140822
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Moodys
QuintilesIMS
Baxter
Merck
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.